(S)-3-cyclohexyl-2-butanone | 33204-51-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (S)-3-cyclohexyl-2-butanone
• 英文别名: (-)(S)-2-Cyclohexyl-butanon-(2)；(S)-3-cyclohexyl-butan-2-one；(S)-3-Cyclohexyl-butan-2-on；(3S)-3-cyclohexylbutan-2-one
• CAS: 33204-51-2
• 化学式: C₁₀H₁₈O
• 分子量: 154.252
• InChiKey: VRXQVTPKEMOWID-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  toluene-4-sulfonic acid-((1RS,2SR)-2-cyclohexyl-1-methyl-propyl ester) 生成 (S)-3-cyclohexyl-2-butanone
  参考文献：
  名称：

  Kirmse,W.; Gruber,W., Chemische Berichte, 1971, vol. 104, p. 1789 - 1794

  摘要：

  DOI：

文献信息

• [EN] IRAK DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION D'IRAK ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2020264499A1

  公开（公告）日：2020-12-30

  The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。这些化合物包括能够结合到IRAK4的IRAK结合基团和诱导降解的基团（DIM）。DIM可以是DTM、一个连接酶结合基团（LBM）或赖氨酸类似物。这些化合物可以作为IRAK蛋白激酶抑制剂，并应用于IRAK介导的疾病。
• Spirocyclic inhibitors of serine proteases for the treatment of hcv infections
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP2631238A1

  公开（公告）日：2013-08-28

  The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.

  本发明涉及式（I）化合物或其药学上可接受的盐。这些化合物可抑制丝氨酸蛋白酶，特别是丙型肝炎病毒 NS3-NS4A 蛋白酶。
• MALT1 inhibitors and uses thereof
  申请人：Cornell University

  公开号：US10711036B2

  公开（公告）日：2020-07-14

  Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, which may be useful as MALT1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, MALT lymphoma), benign neoplasm, a disease associated with angiogenesis, an autoimmune disease, an inflammatory disease, an autoinflammatory disease) by administering a compound of Formula (I).

  本文提供的式(I)化合物及其药物组合物可用作 MALT1 抑制剂。还提供了通过施用式（I）化合物治疗增殖性疾病（如癌症（如非霍奇金淋巴瘤、弥漫大 B 细胞淋巴瘤、MALT 淋巴瘤）、良性肿瘤、与血管生成相关的疾病、自身免疫性疾病、炎症性疾病、自身炎症性疾病）。
• Studies in Stereochemistry. XX. Steric Control of Asymmetric Induction in the Preparation of the 3-Cyclohexyl-2-butanol System¹
  作者：Donald J. Cram、Frederick D. Greene

  DOI：10.1021/ja01119a067

  日期：1953.12
• Chiral synthesis via organoboranes. 30. Facile synthesis, by the Matteson asymmetric homologation procedure, of .alpha.-methyl boronic acids not available from asymmetric hydroboration and their conversion into the corresponding aldehydes, ketones, carboxylic acids, and amines of high enantiomeric purity
  作者：Milind V. Rangaishenvi、Bakthan Singaram、Herbert C. Brown

  DOI：10.1021/jo00010a022

  日期：1991.5

  2-(alpha-Methylalkyl)- or 2-(alpha-arylethyl)-1,3,2-dioxaborinanes, RMeHC*BO2(CH2)3 (R = alkyl or aryl), of very high enantiomeric purity, not available from asymmetric hydroboration, can be prepared by the Matteson asymmetric homologation procedure of optically pure pinanediol or 2,3-butanediol boronate esters with (dichloromethyl)lithium, LiCHCl2, conveniently generated in situ in THF at -78-degrees-C, followed by reaction with either a Grignard reagent or an alkyllithium, with subsequent removal of the chiral auxiliaries. alpha-Methyl boronic esters thus obtained are readily converted into the corresponding aldehydes by the reaction with [methoxy(phenylthio)methyl]lithium [LiCH(OMe)SPh] (MPML) and mercuric chloride, followed by oxidation with hydrogen peroxide in a pH 8 buffer medium. The two-phase aqueous chromic acid procedure can be used to oxidize these aldehydes to the corresponding alpha-methyl carboxylic acids of very high enantiomeric purity without significant racemization. Additionally, pinanediol or 2,3-butanediol alpha-methylorganylboronate esters can be conveniently converted into borinic ester derivatives, RMeHC*BMe(OMe), of very high enantiomeric purity by reaction with methyllithium, followed by treatment with methanolic hydrogen chloride and subsequent recovery of the valuable chiral auxiliaries. These borinic ester derivatives are converted into alpha-methyl ketones and alpha-methyl primary amines of known absolute configuration by the alpha,alpha-dichloromethyl methyl ether (DCME) reaction and the reaction with hydroxylamine-O-sulfonic acid, respectively. The present synthesis of chiral 2-organyl-1,3,2-dioxaborinanes by the Matteson route, together with our direct asymmetric hydroboration procedure, makes it possible to synthesize many chiral boronic acid derivatives in very high enantiomeric purities. These complementary procedures greatly expand the scope of asymmetric synthesis via chiral organoboranes.